Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital Zhejiang UniversityNo recent work listed

Peng Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5479-899X; OpenAlex author ID A5058548650. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
8
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper

Papers 4

  1. Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized-controlled open-label Phase II study. Last author DOI 10.1093/gastro/goac088↗
  2. Correction: Recent development of gene therapy for pancreatic cancer using non-viral nanovectors. Last author DOI 10.1039/d1bm90082j↗
  3. Case Report: Effectiveness of Targeted Treatment in a Patient With Pancreatic Cancer Harboring PALB2 Germline Mutation and KRAS Somatic Mutation. Last author DOI 10.3389/fmed.2021.746637↗
  4. Development, Validation and Comparison of Artificial Neural Network Models and Logistic Regression Models Predicting Survival of Unresectable Pancreatic Cancer. Last author DOI 10.3389/fbioe.2020.00196↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhou Tong · 2 shared papers, 2020–2023 · strength 0.28
  2. Wei Wu · 2 shared papers, 2021 · strength 0.26
  3. Hangyu Zhang · 1 shared paper, 2023 · strength 0.18
  4. Qihan Fu · 1 shared paper, 2023 · strength 0.18
  5. Yu Liu · 1 shared paper, 2021 · strength 0.14
  6. Xintao Shuai · 1 shared paper, 2021 · strength 0.14
  7. Aibin Zhang · 1 shared paper, 2021 · strength 0.12
  8. Yu Liu · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.